This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Sbi Incubation Co., Ltd., Y's Therapeutics Co., Ltd.. Active years: 2008-2011.
Company Filing History:
Years Active: 2008-2011
Title: Teikichi Aoyagi: Innovator in Anti-CD26 Antibodies
Introduction
Teikichi Aoyagi is a notable inventor based in Saitama, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of anti-CD26 antibodies. With a total of two patents to his name, Aoyagi's work has the potential to impact various medical treatments.
Latest Patents
Aoyagi's latest patents focus on anti-CD26 antibodies and methods of use thereof. The inventions provide novel anti-CD26 antibodies and related polypeptides, along with polynucleotides encoding these antibodies and polypeptides. The patents also detail methods for producing these antibodies and polypeptides. Furthermore, they include compositions and cells that comprise the antibodies or polypeptides. The methods outlined in the patents aim to inhibit cell proliferation and treat conditions associated with CD26.
Career Highlights
Throughout his career, Aoyagi has worked with various companies, including Y's Therapeutics Co., Ltd. and Sbi Incubation Co., Ltd. His experience in these organizations has contributed to his expertise in the field of biotechnology and antibody development.
Collaborations
Aoyagi has collaborated with notable individuals in his field, including Peter Peizhi Luo and Pingyu Zhong. These collaborations have likely enriched his research and development efforts.
Conclusion
Teikichi Aoyagi is a distinguished inventor whose work on anti-CD26 antibodies holds promise for advancing medical treatments. His contributions to biotechnology are noteworthy and reflect his commitment to innovation in the field.